Form 4 Filing for Contineum Therapeutics, Inc.

Lori Lyons-Williams, a director at Contineum Therapeutics, Inc., was granted a stock option to acquire 19,000 shares of Class A Common Stock. This option was granted under the company's 2024 Equity Incentive Plan as part of the Non-Employee Director Compensation Program. The option has an exercise price of $14.19 per share and vests fully on June 26, 2027, or at the next annual stockholder meeting, provided continuous service is maintained. The transaction was reported on June 26, 2026.